Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting
Open Access
- 2 June 2022
- journal article
- research article
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 8 (1) , 1-13
Abstract
The pathological hallmark of neurodegenerative diseases is the formation of toxic oligomers by proteins such as alpha-synuclein (aSyn) or microtubule-associated protein tau (Tau). Consequently, such oligomers are promising biomarker candidates for diagnostics as well as drug development. However, measuring oligomers and other aggregates in human biofluids is still challenging as extreme sensitivity and specificity are required. We previously developed surface-based fluorescence intensity distribution analysis (sFIDA) featuring single-particle sensitivity and absolute specificity for aggregates. In this work, we measured aSyn and Tau aggregate concentrations of 237 cerebrospinal fluid (CSF) samples from five cohorts: Parkinson’s disease (PD), dementia with Lewy bodies (DLB), Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), and a neurologically-normal control group. aSyn aggregate concentration discriminates PD and DLB patients from normal controls (sensitivity 73%, specificity 65%, area under the receiver operating curve (AUC) 0.68). Tau aggregates were significantly elevated in PSP patients compared to all other groups (sensitivity 87%, specificity 70%, AUC 0.76). Further, we found a tight correlation between aSyn and Tau aggregate titers among all patient cohorts (Pearson coefficient of correlation r = 0.81). Our results demonstrate that aSyn and Tau aggregate concentrations measured by sFIDA differentiate neurodegenerative disease diagnostic groups. Moreover, sFIDA-based Tau aggregate measurements might be particularly useful in distinguishing PSP from other parkinsonisms. Finally, our findings suggest that sFIDA can improve pre-clinical and clinical studies by identifying those individuals that will most likely respond to compounds designed to eliminate specific oligomers or to prevent their formation.Keywords
Funding Information
- Michael J. Fox Foundation for Parkinson's Research (14977, 009889)
- Michael J. Fox Foundation for Parkinson's Research
- U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (K23-NS11416)
This publication has 51 references indexed in Scilit:
- Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologiesNature Reviews Neuroscience, 2013
- Extracellular Tau Levels Are Influenced by Variability in Tau That Is Associated with TauopathiesJournal of Biological Chemistry, 2012
- α-Synuclein in Central Nervous System and from Erythrocytes, Mammalian Cells, and Escherichia coli Exists Predominantly as Disordered MonomerJournal of Biological Chemistry, 2012
- Potential sources of interference on Abeta immunoassays in biological samplesAlzheimer's Research & Therapy, 2012
- α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregationNature, 2011
- α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort studyThe Lancet Neurology, 2011
- In vivo demonstration that α-synuclein oligomers are toxicProceedings of the National Academy of Sciences, 2011
- Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's DiseaseJournal of Clinical Neurology, 2011
- Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptideNature Reviews Molecular Cell Biology, 2007
- Interface between tauopathies and synucleinopathies: A tale of two proteinsAnnals of Neurology, 2006